inotuzumab ozogamicin
General
High Alert Medication: This medication bears a heightened risk of causing significant patient harm when it is used in error.
Genetic Implications:
Pronunciation:
in-oh-tooz-ue-mab oh-zoe-ga-mye-sin
To hear audio pronunciation of this topic, purchase a subscription or log in.Trade Name(s)
- Besponsa
Ther. Class.
Pharm. Class.
drug-antibody conjugates
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., et al. "Inotuzumab Ozogamicin." Davis's Drug Guide, 19th ed., F.A. Davis Company, 2026. The Washington Manual, www.unboundmedicine.com/washingtonmanual/view/Davis-Drug-Guide/110696/5/inotuzumab_ozogamicin.
Vallerand AHA, Sanoski CAC, . Inotuzumab ozogamicin. Davis's Drug Guide. F.A. Davis Company; 2026. https://www.unboundmedicine.com/washingtonmanual/view/Davis-Drug-Guide/110696/5/inotuzumab_ozogamicin. Accessed April 29, 2026.
Vallerand, A. H., Sanoski, C. A., & , (2026). Inotuzumab ozogamicin. In Davis's Drug Guide (19th ed.). F.A. Davis Company. https://www.unboundmedicine.com/washingtonmanual/view/Davis-Drug-Guide/110696/5/inotuzumab_ozogamicin
Vallerand AHA, Sanoski CAC, . Inotuzumab Ozogamicin [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2026. [cited 2026 April 29]. Available from: https://www.unboundmedicine.com/washingtonmanual/view/Davis-Drug-Guide/110696/5/inotuzumab_ozogamicin.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - inotuzumab ozogamicin
ID - 110696
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
AU - ,,
BT - Davis's Drug Guide
UR - https://www.unboundmedicine.com/washingtonmanual/view/Davis-Drug-Guide/110696/5/inotuzumab_ozogamicin
PB - F.A. Davis Company
ET - 19
DB - The Washington Manual
DP - Unbound Medicine
ER -

Davis's Drug Guide

